Carlos L. Arteaga, M.D., a devoted cancer researcher and clinician, was named Director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center in September 2017. He also serves as Associate Dean of Oncology Programs. Dr. Arteaga is internationally recognized for his work in laboratory-based translational research and advancing the care of breast cancer patients. The majority of Dr. Arteaga’s career has been as a physician-scientist in Medical Oncology at the Vanderbilt-Ingram Cancer Center of Vanderbilt University, where he served as Associate Director for Translational/Clinical Research and Director of the Center for Cancer Targeted Therapies. At Vanderbilt, he also led a successful translational research program that includes a National Cancer Institute/National Institutes of Health SPORE award in breast cancer. He is a member of the American Society for Clinical Investigation and the Association of American Physicians. He has earned numerous accolades from the American Cancer Society, the American Association for Cancer Research (AACR), Susan G. Komen for the Cure Foundation, and the American Society of Clinical Oncology. A former President of the AACR, he serves on the boards of advisors of several cancer centers and breast cancer programs. Dr. Arteaga earned his medical degree from Facultad de Ciencias Médicas at the Universidad de Guayaquil in Ecuador. He trained in Internal Medicine at Emory University and in Medical Oncology at the University of Texas Health Science Center at San Antonio.
- Medical School
- Universidad de Guayaquil, Ecuador (1980)
- Emory University School of Medicine (1984), Internal Medicine
- University of Texas Health Science Center, San Antonio (1988), Hematology Oncology
- Mouse models and anti-HER2 therapies.
- Hanker AB, Cook RS, Arteaga CL Oncotarget 2013 Nov 4 11 1866-7
- Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer.
- Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC Cancer Res. 2013 Oct 73 20 6164-74
- Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.
- Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL Cancer Res. 2013 Oct 73 20 6346-58
- An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
- Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SA Cancer Res. 2013 Oct 73 19 6024-35
- Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110a inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
- Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL Cancer Res. 2013 Oct 73 19 6013-23
- Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
- Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL Clin. Cancer Res. 2013 Oct 19 19 5390-401
- ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
- Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS J. Clin. Invest. 2013 Oct 123 10 4329-43
- Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
- Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL Proc. Natl. Acad. Sci. U.S.A. 2013 Aug 110 35 14372-7
- Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.
- Rexer BN, Arteaga CL Cancer Res. 2013 Jul 73 13 3817-20
- Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
- Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL Cancer Res. 2013 Jul 73 13 4075-85